Last:
Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

GW is the global leader in developing cannabinoid-based medicines. Its lead product candidate, Epidiolex® (cannabidiol), is in development to treat rare and catastrophic forms of childhood-onset epilepsy, potentially offering relief to patients for conditions that previously had few treatment options.